New Alzheimer’s drug said to be 'huge step forward'

June 9, 2021

New Alzheimer’s drug said to be 'huge step forward'

UW Medicine was one of the clinical trial sites for aducanumab, a drug approved yesterday by the Food and Drug Administration to slow the progression of Alzheimer’s disease in people with mild symptoms. Aducanumab is the first drug approved by the FDA to intervene in the biology of Alzheimer’s disease.

"This is a huge step forward. I mean, this is the first disease-modifying therapy for Alzheimer's disease, meaning it actually can change the trajectory of the disease course," said Dr. Charlie Bernick, clinical trials director of UW Medicine's Memory and Brain Wellness Center

The monthly intravenous drug removes amyloid plaque, which is associated with Alzheimer’s. However, debate is ongoing about the quality of study evidence and the degree of benefit conferred by aducanumab.

Access downloadable multimedia files with Dr. Charlie Bernick discussing aducanumab.

See also Q&A on the field of Alzheimer's research.

Getty Images

Terms of appropriate usage of file downloads

  • News reporters and news organizations may freely republish and distribute videos, still images and audio files produced by UW Medicine and the University of Washington School of Medicine.
  • Works must be attributed/credited appropriately (for example, “UW Medicine” – as denoted in the file) and must not be used for commercial purposes.
  • These visual and audio files may not be used to exploit or misrepresent UW Medicine or the University of Washington.
  • UW Medicine often licenses still images from Thinkstock but cannot grant republishing rights. You may not republish single image files credited to Thinkstock.
  • Logos of UW Medicine and University of Washington Health Sciences schools may not be republished without explicit permission. Contact us by phone or email: 206.543.3620 or